Swedish cancer diagnostics company BiBBInstruments AB (Spotlight: BIBB) said on Wednesday that it received additional fourth-quarter orders from its US distributor TaeWoong Medical USA worth USD31,840 (SEK 300k).

The orders form part of a targeted US launch initiated in the autumn.

EndoDrill GI is a powered biopsy instrument for endoscopic ultrasound that holds US Food and Drug Administration clearance and CE marking. The system received US 510(k) clearance in 2023 and CE marking in 2024, is in clinical use in both regions, and began its US launch in autumn 2025.

TaeWoong Medical USA is seeking to establish regular use at major reference hospitals to underpin a nationwide launch in 2026, while BiBBInstruments AB is also in discussions with potential European distribution partners with the aim of a 2026 market entry.

BiBBInstruments AB said fourth-quarter order value to date exceeds third-quarter sales by more than 170%.